Meeting
2016 ASCO Annual Meeting
Immunogenicity of sipuleucel-T (Sip-T) in abiraterone (Abi)/enzalutamide (Enz) sensitive and resistant metastatic castrate-resistant prostate cancer (mCRPC).
Authors
Eric Jay Small
University of California, San Francisco, San Francisco, CA
Eric Jay Small , Lawrence Fong , David I. Quinn , Charles G. Drake , Dwayne Campogan , Tuyen Vu , Nadeem Anwar Sheikh , Nancy N. Chang , Daniel Peter Petrylak
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Prostate) Cancer
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer - Advanced Disease
Clinical Trial Registration Number
NCT01981122 and NCT01487863
Citation
J Clin Oncol 34, 2016 (suppl; abstr 5077)
DOI
10.1200/JCO.2016.34.15_suppl.5077
Abstract #
5077
Poster Bd #
334
Abstract Disclosures
Similar Posters
Poster
2017 Genitourinary Cancers Symposium
Antigen spread (AgS) after sipuleucel-T (sip-T): A cross-trial comparison of 4 sip-T clinical trials of patients (pts) with prostate cancer (PC).
First Author: Lawrence Fong
Poster
2023 ASCO Genitourinary Cancers Symposium
Racial differences in survival and healthcare resource utilization among Medicaid-insured adults with metastatic castration-resistant prostate cancer.
First Author: Maral DerSarkissian
Poster
2020 ASCO Virtual Scientific Program
Radiographic paradoxical response in patients with metastatic castrate-resistant prostate cancer (mCRPC) undergoing treatment with second-generation hormone therapy (second-HT).
First Author: Jamal Alamiri
Poster
2019 Genitourinary Cancers Symposium
Pembrolizumab (pembro) in heavily pretreated metastatic castrate-resistant prostate cancer (mCRPC).
First Author: Marcus Marie Moses